Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Ahmed M, Hassan M, Tahir M, Hussain M, Islam F, Khan GT, Ahsan M, Bin Shafiq S, Ibrahim A, Uddin A, Waqas SA

Diabetes, obesity & metabolism16 Mar 2026Cited by 4 (Europe PMC)

PMID41834765DOI10.1111/dom.70667PepBankPUB-41834765

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in people with obesity, CagriSema reduced percentage body weight more than semaglutide.
In plain wordsIn people with obesity, CagriSema led to more percentage weight loss than semaglutide in pooled trials.
Peptide
Cagrilintide
Outcome
DecreasePercentage change in body weight
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference, percentage weight change
−7.47%
CagriSema vs semaglutide
Source sentences
Summary
Cagrisema produced significantly greater percentage [MD -7.47% (95% CI: -10.58, -4.36); p < 0.001]
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476501
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in people with obesity, CagriSema reduced absolute body weight more than semaglutide.
In plain wordsIn people with obesity, CagriSema led to more weight loss in kilograms than semaglutide in pooled trials.
Peptide
Cagrilintide
Outcome
DecreaseAbsolute change in body weight
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference, absolute weight change
−7.6 kg
CagriSema vs semaglutide
Source sentences
Summary
Cagrisema produced significantly greater percentage [MD -7.47% (95% CI: -10.58, -4.36); p < 0.001] and absolute [MD -7.60 kg (95% CI: -10.33, -4.86); p < 0.001] weight loss than semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476502
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in people with obesity, weight loss with cagrilintide monotherapy was comparable to semaglutide.
In plain wordsIn people with obesity, cagrilintide alone gave weight loss similar to semaglutide in pooled trials.
Peptide
Cagrilintide
Outcome
No significant changeWeight loss with cagrilintide monotherapy
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Cagrilintide monotherapy weight loss was comparable to semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476503
04HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in people with obesity, lipid parameters were mostly similar between CagriSema and semaglutide.
In plain wordsIn people with obesity, blood fats were mostly similar with CagriSema and with semaglutide.
Peptide
Cagrilintide
Outcome
No significant changeLipid parameters
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Lipids parameters were mostly similar between groups
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476504
05HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomised trials in people with obesity, LDL-C was modestly higher with CagriSema than with semaglutide.
In plain wordsIn people with obesity, LDL cholesterol was slightly higher with CagriSema than with semaglutide.
Peptide
Cagrilintide
Outcome
IncreaseLDL-C
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Measurements
Mean difference, LDL-C
0.29 mmol/L
CagriSema vs semaglutide
Source sentences
Summary
LDL-C was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03].
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476505
06HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in people with obesity, overall adverse events were comparable between CagriSema and semaglutide.
In plain wordsIn people with obesity, CagriSema and semaglutide had similar overall rates of side effects.
Peptide
Cagrilintide
Outcome
No significant changeOverall adverse events
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Overall and serious adverse events were comparable between cagrisema and semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476506
07HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in people with obesity, serious adverse events were comparable between CagriSema and semaglutide.
In plain wordsIn people with obesity, CagriSema and semaglutide had similar rates of serious side effects.
Peptide
Cagrilintide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Overall and serious adverse events were comparable between cagrisema and semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476507
08HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in people with obesity, CagriSema increased administration-site conditions compared with semaglutide.
In plain wordsIn people with obesity, CagriSema caused more injection-site problems than semaglutide.
Peptide
Cagrilintide
Outcome
IncreaseAdministration-site conditions
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Risk ratio
3.27 ratio
administration-site conditions
Source sentences
Summary
combination therapy increased administration-site conditions [RR 3.27 (95% CI: 1.27, 8.46)]
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476508
09HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in people with obesity, CagriSema increased nausea compared with semaglutide.
In plain wordsIn people with obesity, CagriSema caused more nausea than semaglutide.
Peptide
Cagrilintide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Risk ratio
1.64 ratio
nausea
Source sentences
Summary
nausea [RR 1.64 (95% CI: 1.01, 2.66)].
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476509
10HumanSystematic reviewSafety outcome
In a meta-analysis of randomised trials in people with obesity, cagrilintide monotherapy carried a higher risk of serious adverse events than semaglutide.
In plain wordsIn people with obesity, cagrilintide alone had a higher risk of serious side effects than semaglutide.
Peptide
Cagrilintide
Outcome
IncreaseSerious adverse events with cagrilintide monotherapy
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Risk ratio
1.83 ratio
serious adverse events
Source sentences
Summary
Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Report a problemFND-4183476510

Studies that did not test the peptide alone8

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) produced greater percent weight loss than semaglutide alone.
In plain wordsIn adults with obesity, the CagriSema combination led to more weight loss than semaglutide alone.
Peptide
Semaglutide
Outcome
DecreasePercent body weight change
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.47%
percent weight change vs semaglutide
Source sentences
Summary
Cagrisema produced significantly greater percentage [MD -7.47% (95% CI: -10.58, -4.36); p < 0.001] and absolute [MD -7.60 kg (95% CI: -10.33, -4.86); p < 0.001] weight loss than semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476511
12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) produced greater absolute weight loss than semaglutide alone.
In plain wordsIn adults with obesity, the CagriSema combination led to more kilograms lost than semaglutide alone.
Peptide
Semaglutide
Outcome
DecreaseAbsolute body weight change
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.6 kg
absolute weight change vs semaglutide
Source sentences
Summary
Cagrisema produced significantly greater percentage [MD -7.47% (95% CI: -10.58, -4.36); p < 0.001] and absolute [MD -7.60 kg (95% CI: -10.33, -4.86); p < 0.001] weight loss than semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476512
13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, lipid parameters were mostly similar between CagriSema (semaglutide plus cagrilintide) and semaglutide alone.
In plain wordsIn adults with obesity, blood fat levels were mostly similar with the CagriSema combination and with semaglutide alone.
Peptide
Semaglutide
Outcome
No significant changeLipid parameters
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Lipids parameters were mostly similar between groups
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476513
14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, LDL cholesterol was modestly higher with CagriSema (semaglutide plus cagrilintide) than with semaglutide alone.
In plain wordsIn adults with obesity, LDL cholesterol was slightly higher with the CagriSema combination than with semaglutide alone.
Peptide
Semaglutide
Outcome
IncreaseLDL cholesterol
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Lipids · Metabolic and weight
Measurements
Mean difference
0.29 mmol/L
LDL-C vs semaglutide
Source sentences
Summary
though LDL-C was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03].
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476514
15HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity, overall adverse events were comparable between CagriSema (semaglutide plus cagrilintide) and semaglutide alone.
In plain wordsIn adults with obesity, the overall rate of side effects was similar with the CagriSema combination and with semaglutide alone.
Peptide
Semaglutide
Outcome
No significant changeOverall adverse events
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Source sentences
Summary
Overall and serious adverse events were comparable between cagrisema and semaglutide,
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476515
16HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity, serious adverse events were comparable between CagriSema (semaglutide plus cagrilintide) and semaglutide alone.
In plain wordsIn adults with obesity, serious side effects were similar with the CagriSema combination and with semaglutide alone.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Source sentences
Summary
Overall and serious adverse events were comparable between cagrisema and semaglutide,
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476516
17HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) increased administration-site conditions versus semaglutide alone.
In plain wordsIn adults with obesity, injection-site problems were more common with the CagriSema combination than with semaglutide alone.
Peptide
Semaglutide
Outcome
IncreaseAdministration-site conditions
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Adverse events · Whole body
Measurements
Risk ratio
3.27 RR
administration-site conditions vs semaglutide
Source sentences
Summary
combination therapy increased administration-site conditions [RR 3.27 (95% CI: 1.27, 8.46)]
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476517
18HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity, CagriSema (semaglutide plus cagrilintide) increased nausea versus semaglutide alone.
In plain wordsIn adults with obesity, nausea was more common with the CagriSema combination than with semaglutide alone.
Peptide
Semaglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Risk ratio
1.64 RR
nausea vs semaglutide
Source sentences
Summary
combination therapy increased administration-site conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss.
Summary · context
Three RCTs (n = 3545) were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4183476518

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Summary

Results from this study18

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords